A maternal vaccine for group B streptococcal infection and a drug for treating a severely disabling bone disorder have become the first two investigational products to make it onto the European Medicines Agency’s PRIME (priority medicines) scheme this year.
The GBS6 vaccine, from Pfizer, and BioCryst Pharmaceuticals’ BCX9250 drug for fibrodysplasia ossificans progressiva (FOP) were accepted onto...








